Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TASOX versus FOLFOX in advanced gastric, esophageal, or gastroesophageal junction adenocarcinoma
2022-000273-81Phase 2Active
- Sponsor
- Unicancer
- Start
- Jul 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trifluridine + tipiracil, oxaliplatin, folinic acid and fluorouracil in gastric adenocarcinoma, esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival. Started Jul 2022; status: active.
02
Drugs
trifluridine + tipiraciloxaliplatinfolinic acidfluorouracil
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2022-000273-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000273-81.